Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

BACKGROUND: In light of the increased risk of progressive multifocal encephalopathy (PML) development under long-term treatment with the monoclonal antibody natalizumab which is approved for treatment of active relapsing remitting multiple sclerosis (RRMS), there is a clear need for alternative trea...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Neurol
Autors principals: Klotz, Luisa, Grützke, Berit, Eveslage, Maria, Deppe, Michael, Gross, Catharina C., Kirstein, Lucienne, Posevitz-Fejfar, Anita, Schneider-Hohendorf, Tilman, Schwab, Nicholas, Meuth, Sven G., Wiendl, Heinz
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4477482/
https://ncbi.nlm.nih.gov/pubmed/26099927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0354-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars